Details for Patent: 7,855,211
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 7,855,211 protect, and when does it expire?
Patent 7,855,211 protects VERZENIO and is included in one NDA.
This patent has fifty patent family members in forty-four countries.
Summary for Patent: 7,855,211
Title: | Protein kinase inhibitors |
Abstract: | The present invention provides a compound of formula (I): ##STR00001## or a pharmaceutically acceptable salt thereof which is useful in the treatment of cell proliferative diseases. |
Inventor(s): | Coates; David A (Indianapolis, IN), Gelbert; Lawrence Mark (Indianapolis, IN), Knobeloch; John M. (Indianapolis, IN), De Dios Magana; Alfonso (Carmel, IN), De Prado Gonzalez; Ana (Madrid, ES), Filadelfa Del Prado Catalina; Miriam (Madrid, ES), Garcia Paredes; Maria Cristina (Madrid, ES), Martin De La Nava; Eva Maria (Madrid, ES), Martin Ortega Finger; Maria Dolores (Madrid, ES), Martinez Perez; Jose Antonio (Madrid, ES), Mateo Herranz; Ana Isabel (Madrid, ES), Perez Martinez; Carlos (Madrid, ES), Sanchez Martinez; Concepcion (Madrid, ES) |
Assignee: | Eli Lilly and Company (Indianapolis, IN) |
Application Number: | 12/637,789 |
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Compound; |
Drugs Protected by US Patent 7,855,211
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly And Co | VERZENIO | abemaciclib | TABLET;ORAL | 208716-001 | Sep 28, 2017 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | Y | IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER | See Plans and Pricing | ||
Eli Lilly And Co | VERZENIO | abemaciclib | TABLET;ORAL | 208716-001 | Sep 28, 2017 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | Y | IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY | See Plans and Pricing | ||
Eli Lilly And Co | VERZENIO | abemaciclib | TABLET;ORAL | 208716-001 | Sep 28, 2017 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | Y | AS MONOTHERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY AND PRIOR CHEMOTHERAPY IN THE METASTATIC SETTING | See Plans and Pricing | ||
Eli Lilly And Co | VERZENIO | abemaciclib | TABLET;ORAL | 208716-001 | Sep 28, 2017 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | Y | IN COMBINATION WITH ENDOCRINE THERAPY (TAMOXIFEN OR AN AROMATASE INHIBITOR) FOR THE ADJUVANT TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE, NODE-POSITIVE, EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE AND A KI-67 SCORE >=20% | See Plans and Pricing | ||
Eli Lilly And Co | VERZENIO | abemaciclib | TABLET;ORAL | 208716-001 | Sep 28, 2017 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | Y | IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDROCRINE THERAPY | See Plans and Pricing | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 7,855,211
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
08380343 | Dec 22, 2008 |
International Family Members for US Patent 7,855,211
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 074575 | See Plans and Pricing | |||
Australia | 2009330365 | See Plans and Pricing | |||
Brazil | PI0924183 | See Plans and Pricing | |||
Canada | 2747055 | See Plans and Pricing | |||
Chile | 2011001527 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |